) recently announced that the company obtained license for its
RealTime High Risk HPV molecular diagnostic test from the Medical
Device Bureau of Health Canada.
Abbott Labs' RealTime High Risk HPV molecular diagnostic test
enables detection of human papillomavirus (HPV) which is the
prime cause of cervical cancer.
The test is performed on the Abbott Labs' m2000 RealTime
molecular diagnostics system and is already available in the US
We note that Abbott Labs continues to invest in the
development of next-generation instruments and other advanced
technologies in its diagnostics business.
Molecular diagnostics continues to be a key area of focus and
Abbott Labs expects accelerated growth from molecular diagnostics
in the second quarter of 2013 along with increased revenues from
core laboratory and point of care diagnostics business.
In Apr 2013, Abbott Labs launched a laboratory automation
track system ACCELERATOR a3600, which is a next-generation track
system to increase efficiency in laboratories.
Meanwhile, the nutrition business also holds promise and
Abbott Labs expects accelerated growth from both the nutrition
and diagnostics businesses in 2013.
We remind investors that Abbott Labs became a diversified
medical products company focusing on branded generic
pharmaceutical, medical devices, diagnostic and nutritional
businesses following the separation of its research-based
pharmaceuticals business into a new company,
), in Jan 2013.
We believe the diversification bodes well for Abbott Labs and
should enable the company to counter the challenging business
environment as a result of austerity measures undertaken by
developed markets in 2013 coupled with weak economic conditions
and a mixed global economy.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
) look well placed with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ATRICURE INC (ATRC): Free Stock Analysis
TRANS1 INC (TSON): Free Stock Analysis Report
To read this article on Zacks.com click here.